Dr Annabel Goodwin

Clinical Senior Lecturer
Medicine, Concord Clinical School

Telephone 02 9845 6947

Map

Keywords

Cancer

Selected grants

2017

  • Cochrane Breast Cancer Group; Wilcken N, Goodwin A, O'Connell D, Tan-Koay A, Berber S, Willson M, Bulsara M, Norris S, Stuart K, Hickey B, Saunders C, Simes R; National Health and Medical Research Council (NHMRC)/Cochrane Collaboration Funding.

2014

  • Cochrane Breast Cancer Group infrastructure funding for support and development of reliable and relevant systematic ‘Cochrane’ reviews in breast cancer; Wilcken N, Goodwin A; National Breast Cancer Foundation/Research Services.

2006

  • Validation of a questionnaire about the family history of bowel cancer; Goodwin A; Cancer Institute New South Wales/Fellowship.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Star, P., Goodwin, A., Kapoor, R., Conway, R., Long, G., Scolyer, R., Guitera, P. (2018). Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. European Journal of Cancer, 92, 48-53. [More Information]
  • O'Carrigan, B., Wong, M., Willson, M., Stockler, M., Pavlakis, N., Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2017 (10), 1-210. [More Information]
  • Lee, C., Goodwin, A., Wilcken, N. (2017). Fulvestrant for hormone-sensitive metastatic breast cancer. Cochrane Database of Systematic Reviews, 2017 (1), 1-59. [More Information]
  • Zaheed, M., Wilcken, N., Willson, M., O'Connell, D., Goodwin, A. (2017). Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer (Protocol). Cochrane Database of Systematic Reviews, 2017 (11), 1-12. [More Information]
  • Goodwin, A., Willson, M., Wilcken, N. (2016). High dose, high risk? What updated evidence tells us about chemotherapy dosing in early breast cancer. Cochrane Database of Systematic Reviews, 5, 1-3.
  • Mocellin, S., Goodwin, A., Pasquali, S. (2016). Risk-reducing medication for primary breast cancer: A network meta-analysis. Cochrane Database of Systematic Reviews, 2016 (5), 1-18. [More Information]

2018

  • Star, P., Goodwin, A., Kapoor, R., Conway, R., Long, G., Scolyer, R., Guitera, P. (2018). Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. European Journal of Cancer, 92, 48-53. [More Information]

2017

  • O'Carrigan, B., Wong, M., Willson, M., Stockler, M., Pavlakis, N., Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2017 (10), 1-210. [More Information]
  • Lee, C., Goodwin, A., Wilcken, N. (2017). Fulvestrant for hormone-sensitive metastatic breast cancer. Cochrane Database of Systematic Reviews, 2017 (1), 1-59. [More Information]
  • Zaheed, M., Wilcken, N., Willson, M., O'Connell, D., Goodwin, A. (2017). Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer (Protocol). Cochrane Database of Systematic Reviews, 2017 (11), 1-12. [More Information]

2016

  • Goodwin, A., Willson, M., Wilcken, N. (2016). High dose, high risk? What updated evidence tells us about chemotherapy dosing in early breast cancer. Cochrane Database of Systematic Reviews, 5, 1-3.
  • Mocellin, S., Goodwin, A., Pasquali, S. (2016). Risk-reducing medication for primary breast cancer: A network meta-analysis. Cochrane Database of Systematic Reviews, 2016 (5), 1-18. [More Information]

To update your profile click here. For support on your academic profile contact .